Selmod
Selmod is a Swiss biotech start-up focused on developing innovative antibiotics for the treatment of life-threatening, multi-drug resistant infections. They specialize in discovery and early clinical development of small molecules and peptides against new targets or mechanisms of action, aiming to address the growing threat of antimicrobial resistance. Supported by venture capital and research institutions, Selmod aims to bring disruptive therapies to market and ultimately save lives.
Industries
Nr. of Employees
small (1-50)
Products
Antimicrobial development candidates (three preclinical projects; lead: slm500)
A portfolio of three novel antimicrobial candidates in preclinical development, with a lead program (slm500) advancing toward preclinical proof-of-concept and intended progression into early clinical development.
Antimicrobial development candidates (three preclinical projects; lead: slm500)
A portfolio of three novel antimicrobial candidates in preclinical development, with a lead program (slm500) advancing toward preclinical proof-of-concept and intended progression into early clinical development.
Services
Establishing research collaborations and in-licensing arrangements to build and diversify a preclinical antimicrobial portfolio.
Capital raising activities to fund preclinical research and progression of early antimicrobial candidates.
Establishing research collaborations and in-licensing arrangements to build and diversify a preclinical antimicrobial portfolio.
Capital raising activities to fund preclinical research and progression of early antimicrobial candidates.
Expertise Areas
- Antibacterial and antifungal drug discovery
- Preclinical proof-of-concept development
- Early clinical development (Phase I–II)
- Medicinal chemistry and novel modality design
Key Technologies
- Small-molecule drug discovery
- Peptide therapeutics
- Bacteriophage-inspired discovery methods
- Molecular biology techniques